{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:18:39Z","timestamp":1790788719657,"version":"4.1.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":256,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ono Pharmaceuticals Co. Ltd."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tirabrutinib, a second-generation inhibitor of Bruton\u2019s tyrosine kinase, was approved in March 2020 for the treatment of relapsed or refractory primary central nervous system lymphoma (r\/r PCNSL) based on phase I\/II studies in Japan. We previously reported the overall response rate and safety profile. We describe Karnofsky Performance Status (KPS) and the quality of life (QoL) in patients with r\/r PCNSL receiving tirabrutinib based on more than 1-year follow-up data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with r\/r PCNSL, age \u226520 years, and KPS \u226570 were treated with tirabrutinib once daily at a dose of 320, 480, or 480 mg under fasted conditions. QoL was assessed using questionnaires issued by the European Organization for Research and Treatment of Cancer (EORTC), namely EORTC QLQ-C30, EORTC QLQ-BN20, and EuroQol 5 dimensions 3-level (EQ-5D-3L) along with KPS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty-four patients (mean age, 60 years [range 29\u201386]) were enrolled. The median follow-up period was 14.9 months (range, 1.4\u201327.7). The median KPS of the patients at baseline was 80.0 (range, 70\u2013100), and this remained constant during the treatment. The global health status\/QoL in the QLQ-C30 showed significant improvements from baseline through cycles 3\u201317 and remained relatively constant thereafter until cycle 23. Improvements were also seen in emotional functioning and constipation in the QLQ-C30 segments. Other items of QLQ-C30 and QLQ-BN20, EQ-5D visual analog scales, and EQ-5D index were maintained during the treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tirabrutinib generally maintains KPS and QoL scores with some improvements in specific QoL items in patients with r\/r PCNSL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/noajnl\/vdad109","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T17:04:59Z","timestamp":1694538299000},"source":"Crossref","is-referenced-by-count":6,"title":["Karnofsky Performance Status and quality of life in patients with relapsed or refractory primary CNS lymphoma from a phase I\/II study of tirabrutinib"],"prefix":"10.1093","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4626-4645","authenticated-orcid":false,"given":"Yoshiki","family":"Arakawa","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Kyoto University Graduate School of Medicine , Kyoto , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4303-6006","authenticated-orcid":false,"given":"Yoshitaka","family":"Narita","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0018-1652","authenticated-orcid":false,"given":"Motoo","family":"Nagane","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kyorin University Faculty of Medicine , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Mishima","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology\/Neurosurgery, Saitama Medical University International Medical Center , Saitama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhito","family":"Terui","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Yonezawa","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kagoshima University Hospital , Kagoshima , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Asai","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Osaka International Cancer Institute , Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2682-2179","authenticated-orcid":false,"given":"Noriko","family":"Fukuhara","sequence":"additional","affiliation":[{"name":"Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine , Miyagi , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Sugiyama","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology & Neuro-Oncology Program, Hiroshima University Hospital , Hiroshima , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3352-7936","authenticated-orcid":false,"given":"Naoki","family":"Shinojima","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Kumamoto University Hospital , Kumamoto , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arata","family":"Aoi","sequence":"additional","affiliation":[{"name":"Ono Pharmaceutical Co, Ltd , Osaka , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5617-8068","authenticated-orcid":false,"given":"Ryo","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology\/Neurosurgery, Saitama Medical University International Medical Center , Saitama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"issue":"9","key":"2023092304044128000_CIT0001","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1080\/10428194.2018.1563294","article-title":"Staging identifies non-CNS malignancies in a large cohort with newly diagnosed lymphomatous brain lesions","volume":"60","author":"Malani","year":"2019","journal-title":"Leuk Lymphoma."},{"issue":"2","key":"2023092304044128000_CIT0002","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-006-9165-6","article-title":"Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors","volume":"80","author":"Jahnke","year":"2006","journal-title":"J Neurooncol."},{"key":"2023092304044128000_CIT0003","doi-asserted-by":"crossref","first-page":"20406207211066166","DOI":"10.1177\/20406207211066166","article-title":"Primary central nervous system lymphoma in the United States, 1975-2017","volume":"13","author":"Lv","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"2023092304044128000_CIT0004","volume-title":"Brain Tumor Treatment Guidelines","author":"Japan Society of Neuro-Oncology","year":"2016","edition":"2016"},{"issue":"Suppl 1","key":"2023092304044128000_CIT0005","first-page":"9","article-title":"Brain Tumor Registry of Japan (2005-2008)","volume":"57","year":"2017","journal-title":"Neurol Med Chir (Tokyo)."},{"issue":"Suppl 2","key":"2023092304044128000_CIT0006","first-page":"187","article-title":"Incidence of brain tumors in Japan","volume":"79","author":"Narita","year":"2021","journal-title":"Nihon Rinsho"},{"key":"2023092304044128000_CIT0007","author":"National Comprehensive Cancer Network"},{"key":"2023092304044128000_CIT0008","doi-asserted-by":"crossref","first-page":"8","DOI":"10.21037\/aol-20-47","article-title":"Primary central nervous system lymphoma: a narrative review of ongoing clinical trials and goals for future studies","volume":"5","author":"Schaff","year":"2021","journal-title":"Ann Lymphoma"},{"issue":"1","key":"2023092304044128000_CIT0009","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0360-3016(92)90538-S","article-title":"Non-Hodgkin\u2019s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315","volume":"23","author":"Nelson","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"22","key":"2023092304044128000_CIT0010","first-page":"5034","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"Clin Oncol"},{"issue":"7","key":"2023092304044128000_CIT0011","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1093\/annonc\/mdl464","article-title":"Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines","volume":"18","author":"Correa","year":"2007","journal-title":"Ann Oncol."},{"issue":"1","key":"2023092304044128000_CIT0012","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1212\/WNL.0b013e318297eeba","article-title":"Long-term cognitive function, neuroimaging, and quality of life in primary CNS lymphoma","volume":"81","author":"Doolittle","year":"2013","journal-title":"Neurology."},{"issue":"9","key":"2023092304044128000_CIT0013","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1200\/JCO.2013.53.0808","article-title":"Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia","volume":"32","author":"Bhojwani","year":"2014","journal-title":"J Clin Oncol."},{"issue":"3","key":"2023092304044128000_CIT0014","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1212\/01.WNL.0000106941.51340.A2","article-title":"Treatment-induced leukoencephalopathy in primary CNS lymphoma: a clinical and autopsy study","volume":"62","author":"Lai","year":"2004","journal-title":"Neurology."},{"issue":"17","key":"2023092304044128000_CIT0015","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1200\/JCO.2000.18.17.3144","article-title":"Treatment for primary CNS lymphoma: the next step","volume":"18","author":"Abrey","year":"2000","journal-title":"J Clin Oncol."},{"issue":"1","key":"2023092304044128000_CIT0016","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1093\/neuonc\/noaa145","article-title":"Phase I\/II study of tirabrutinib, a second-generation Bruton\u2019s tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma","volume":"23","author":"Narita","year":"2021","journal-title":"Neuro Oncol"},{"issue":"Suppl 2","key":"2023092304044128000_CIT0017","doi-asserted-by":"crossref","first-page":"ii57","DOI":"10.1093\/neuonc\/noaa215.232","article-title":"One-year follow-up data of phase I\/II study of tirabrutinib in patients with relapsed or refractory primary central nervous system lymphoma","volume":"22","author":"Mishima","year":"2020","journal-title":"Neuro Oncol"},{"issue":"8","key":"2023092304044128000_CIT0018","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/neuonc\/noab037","article-title":"Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients","volume":"23","author":"Dirven","year":"2021","journal-title":"Neuro Oncol"},{"key":"2023092304044128000_CIT0019","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual Life Outcomes"},{"issue":"8","key":"2023092304044128000_CIT0020","doi-asserted-by":"crossref","first-page":"e407","DOI":"10.1016\/S1470-2045(18)30356-5","article-title":"Cognitive functioning and health-related quality of life in patients with newly diagnosed primary CNS lymphoma: a systematic review","volume":"19","author":"van der Meulen","year":"2018","journal-title":"Lancet Oncol."},{"issue":"3","key":"2023092304044128000_CIT0021","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3892\/mco.2016.962","article-title":"Health-related quality of life in outpatients with primary central nervous system lymphoma after radiotherapy and high-dose methotrexate chemotherapy","volume":"5","author":"Okita","year":"2016","journal-title":"Mol Clin Oncol"},{"issue":"9","key":"2023092304044128000_CIT0022","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1007\/s00432-017-2423-5","article-title":"Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial","volume":"143","author":"Herrlinger","year":"2017","journal-title":"J Cancer Res Clin Oncol."}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdad109\/51551507\/vdad109.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/5\/1\/vdad109\/51728213\/vdad109.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/5\/1\/vdad109\/51728213\/vdad109.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T00:06:23Z","timestamp":1695427583000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdad109\/7273663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdad109","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2023,1,1]]},"article-number":"vdad109"}}